MODERNA, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 125 USD | -0.47% |
|
+15.77% | +25.69% |
| 03/05 | Jefferies Adjusts Price Target on Moderna to $155 From $125 | MT |
| 03/05 | Oppenheimer Adjusts Price Target on Moderna to $163 From $142 | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Calendar
06/05/2024
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
125
USD
Average target price
138.3
USD
Spread / Average Target
+10.65%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +25.69% | 47.9B | |
| +46.90% | 41.42B | |
| -3.46% | 40.7B | |
| -6.20% | 28.92B | |
| +9.17% | 25.55B | |
| -20.42% | 19.27B | |
| +0.17% | 12.15B | |
| +28.07% | 12.14B | |
| -1.24% | 11.99B | |
| +19.33% | 11.64B |
- Stock Market
- Equities
- MRNA Stock
- News Moderna, Inc.
- CDC Cautions State Health Officials Not to Give COVID Boosters Until FDA Regulatory Action and CDC Recommendation: Washington Post
